The Thrombosis Research Institute, London, UK (registered charity number, 800365) was established in 1989, with the backing of the then Prime Minister, Margaret Thatcher, specifically to conduct research into cardiovascular disease (of the heart and blood vessels), a major cause of death and disability throughout the world.
This was followed in 2006, with the founding of the Thrombosis Research Institute, Bangalore, India (registered charity number BNG (U) ANKL S.R/D. No. 117/03-04). Officially opened and dedicated to the Nation by the then President of India, His Excellency Dr A P J Abdul Kalam, this second facility has been set up to study the genetics of heart disease particularly among the South Asian population, who seem to have specific predisposing genetic characteristics and to develop novel and affordable therapies for disease prevention and treatment.
The two partner institutions contribute to a joint, independent research programme under the direction of our two Boards of Trustees in London and Bangalore.
Remarkably, the TRI, which opened its London base 20 years ago, consistently exceeds all expectations of what an institute with limited resources can offer genuinely leading research worldwide and driving through bold innovations. Breakthrough contributions already include development of the blood thinning agent heparin which saves 300,000 lives worldwide each year. Others include its demonstration of how commonly fatal clots occur post-surgery; how these discoveries lead to more effective forms of treatment; the role blood clotting plays in cancer, and how anti-clotting drugs may be of use in the care of cancer patients.
For more information visit www.tri-london.ac.uk